Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The V617F JAK2 mutation and the myeloproliferative disorders.

Hematological oncology - 1 Jan 2000

Percy Melanie J, McMullin Mary Frances

Abstract excerpt

The discovery this year of a single mutation in the Janus Kinase (JAK)-2 gene in a high percentage of cases of polycythaemia vera (PV), essential thrombocythaemia (ET) and myelofibrosis suggests that it maybe the underlying molecular mechanism for these disorders. Different approaches from the inhibition of the tyrosine kinase JAK2, widespread search for mutations in tyrosine kinases, and investigation of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chromosomes, Human, Pair 9
Share to Enzyme Activation
Share to Janus Kinase 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Myeloproliferative Disorders

Share to Phenylalanine

Share to Protein-Tyrosine Kinases

Share to Proto-Oncogene Proteins

Share to Valine

Source

Identifiers

PMID: 16285006
DOI: 10.1002/hon.761

Genes

JAK2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The V617F JAK2 mutation and the myeloproliferative disorders.PMID 16285006Read ↗

The JAK2(V617F) tyrosine kinase mutation in myeloproliferative disorders: Summary of published literature and a perspective.Semantic proximity Read ↗

Clinical implications of JAK2 mutations in myeloproliferative disorders.Semantic proximity Read ↗

The JAK2 mutation.Semantic proximity Read ↗

JAK-2 mutations and their relevance to myeloproliferative diseaseSemantic proximity Read ↗

JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science.Semantic proximity Read ↗

Pathogenetic role of JAK2 V617F mutation in chronic myeloproliferative disorders.Semantic proximity Read ↗

A role for JAK2 mutations in myeloproliferative diseases.Semantic proximity Read ↗

JAK2 V617F: a single mutation in the myeloproliferative group of disorders.Semantic proximity Read ↗

Molecular and genetic bases of myeloproliferative disorders: questions and perspectives.Semantic proximity Read ↗

A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases.Semantic proximity Read ↗

The JAK2V617F mutation in polycythemia vera and other myeloproliferative disorders: one mutation for three diseases?Semantic proximity Read ↗

Role of JAK-STAT Signaling in the Pathogenesis of Myeloproliferative DisordersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.